Press Releases NextCell Pharma AB

Equities

NXTCL

SE0009723125

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
1.29 ^SEK	-1.53%		-5.15%	-50.95%

Jun. 12	Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study	CI
May. 28	NextCell Pharma AB Announces Single Treatment with ProTrans Demonstrates Long-Term Therapeutic Effect over 5 Years	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue	Jul. 03	AQ
NextCell's rights issue oversubscribed	Jun. 17	AQ
The paediatric diabetes study gets the green light to treat the age group 7 - 11 years	Jun. 12	AQ
The Board of Directors and management sign in addition to subscription commitments	Jun. 11	AQ
NextCell publishes supplement to the prospectus regarding the rights issue	Jun. 10	AQ
Cellaviva becomes an independent company under NextCell Pharma	Jun. 05	AQ
NextCell procures top guarantee in ongoing rights issue	Jun. 04	AQ
The subscription period in NextCell's rights issue commences today	May. 31	AQ
NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million	May. 30	AQ
Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years	May. 28	AQ
Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)	May. 27	AQ
NextCell publishes its Interim Report 2 2023/2024	Apr. 25	AQ
Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)	Apr. 24	AQ
The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting	Apr. 24	AQ
NextCell's daughter company Cellaviva granted permission to handle amniotic tissue	Apr. 22	AQ
Anders Essen-Möller resigns as Chairman of the Board of Directors due to health reasons	Apr. 19	AQ
The Swedish Medical Products Agency approves subgroup analysis in NextCell's ProTrans-Young study	Mar. 27	AQ
NextCell establishes QVance to meet the Nordic's need for quality analytics	Mar. 14	AQ
NextCell Pharma's updated growth strategy	Feb. 27	AQ
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy	Feb. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NextCell Pharma AB

Equities

NXTCL

SE0009723125

Press Releases

Filters